Correction: Transcriptome analysis of intestine from alk-SMase knockout mice reveals the effect of alk-SMase

Correction: Transcriptome analysis of intestine from alk-SMase knockout mice reveals the effect of alk-SMase

Bibliographic Details
Main Authors:	Jiang Zhu, Lingqi Wang, Zhongwu Guo, Tao Zhang, Ping Zhang
Format:	Article
Language:	English
Published:	BMC 2022-11-01
Series:	Cancer Cell International
Online Access:	https://doi.org/10.1186/s12935-022-02795-5

Similar Items

Transcriptome analysis of intestine from alk-SMase knockout mice reveals the effect of alk-SMase
by: Jiang Zhu, et al.
Published: (2022-11-01)

Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice
by: Carolyn Tallon, et al.
Published: (2022-09-01)

Microglial-Targeted nSMase2 Inhibitor Fails to Reduce Tau Propagation in PS19 Mice
by: Meixiang Huang, et al.
Published: (2023-09-01)

Neuronal deletion of nSMase2 reduces the production of Aβ and directly protects neurons
by: Sehmus Tohumeken, et al.
Published: (2023-02-01)

Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model
by: Carolyn Tallon, et al.
Published: (2023-12-01)

Chronic nSMase inhibition suppresses neuronal exosome spreading and sex-specifically attenuates amyloid pathology in APP knock-in Alzheimer's disease mice
by: Francesca E. Mowry, et al.
Published: (2023-08-01)

Sphingomyelinase D Activity in <i>Sicarius tropicus</i> Venom: Toxic Potential and Clues to the Evolution of SMases D in the Sicariidae Family
by: Priscila Hess Lopes, et al.
Published: (2021-04-01)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma
by: Bhawana George, et al.
Published: (2023-06-01)

ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib
by: Jikui Guan, et al.
Published: (2024-01-01)

Allosteric Inhibition of Neutral Sphingomyelinase 2 (nSMase2) by DPTIP: From Antiflaviviral Activity to Deciphering Its Binding Site through In Silico Studies and Experimental Validation
by: Hadrián Álvarez-Fernández, et al.
Published: (2022-11-01)

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
by: Juanjuan Xiao, et al.
Published: (2022-09-01)

B and CTL responses to the ALK protein in patients with ALK-positive ALCL.
by: Ait-Tahar, K, et al.
Published: (2006)

Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report
by: Jie Huang, PhD, et al.
Published: (2022-06-01)

Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
by: Giovanni Maria Iannantuono, et al.
Published: (2022-04-01)

Inhibiting ALK2/ALK3 Signaling to Differentiate and Chemo-Sensitize Medulloblastoma
by: Doria Filipponi, et al.
Published: (2022-04-01)

A non-functional 5′ ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report
by: Hong Yang, et al.
Published: (2022-10-01)

Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via <i>nSMase2/Smpd3</i>, Satellite, and Immune Cells in Duchenne Muscular Dystrophy
by: Yasunari Matsuzaka, et al.
Published: (2022-01-01)

ALK-1-YNYLLEAD TRIACETATES AS ALK-1-YNYL CARBOCATION EQUIVALENTS - THE ALPHA-ALK-1-YNYLATION OF BETA-DICARBONYL COMPOUNDS AND NITRONATE SALTS
by: Moloney, M, et al.
Published: (1986)

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
by: Zhifeng Ye, et al.
Published: (2023-03-01)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-12-01)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
by: Serena Stadler, et al.
Published: (2018-04-01)

A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
by: Bei Zheng, et al.
Published: (2023-08-01)

ALK protein expression in rhabdomyosarcomas
by: Pillay, K, et al.
Published: (2002)

The selectivity and inhibition of AlkB.
by: Welford, R, et al.
Published: (2003)

ALK protein expression in rhabdomyosarcomas.
by: Pillay, K, et al.
Published: (2002)

Correction: ALK inhibitors in ALK-rearranged nonsmall cell lung cancer with and without brain metastases: systematic review and network meta-analysis
Published: (2022-11-01)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
by: Savvas Papageorgiou, et al.
Published: (2022-07-01)

TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK+ T‐cell lymphoma
by: Wenyu Shi, et al.
Published: (2017-09-01)

Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer
by: Dafeng Guo, et al.
Published: (2022-12-01)

A highly selective chemical probe for activin receptor-like kinases ALK4 and ALK5
by: Hanke, T, et al.
Published: (2020)

A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
by: Josephina Sampson, et al.
Published: (2022-02-01)

PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK‐rearranged lung cancer
by: Sarang S. Talwelkar, et al.
Published: (2023-05-01)

ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
by: Fang Zhang, et al.
Published: (2022-09-01)

The role of demethylase AlkB homologs in cancer
by: Qiao Li, et al.
Published: (2023-03-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review
by: Zhu Zeng, et al.
Published: (2022-10-01)

ALKing the flames of lung cancer immunosensitivity
by: Richard Bayliss, et al.
Published: (2023-11-01)

ALK in Neuroblastoma: Biological and Therapeutic Implications
by: Ricky M. Trigg, et al.
Published: (2018-04-01)

Targeting Autophagy in ALK-Associated Cancers
by: Julie Frentzel, et al.
Published: (2017-11-01)